Leap Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a LPTX research report →
Companywww.leaptx.com
Leap Therapeutics, Inc. , a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers.
- CEO
- Douglas E. Onsi
- IPO
- 2017
- Employees
- 52
- HQ
- Cambridge, MA, US
Price Chart
Valuation
- Market Cap
- $31.86M
- P/E
- -3.59
- P/S
- 0.00
- P/B
- 2.42
- EV/EBITDA
- -2.10
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -46.86%
- ROIC
- -35.50%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $4.82M · 107.14%
- EPS
- $0.07 · 104.03%
- Op Income
- $-36,540,000
- FCF YoY
- 27.19%
Performance & Tape
- 52W High
- $3.58
- 52W Low
- $0.22
- 50D MA
- $0.71
- 200D MA
- $0.45
- Beta
- 0.09
- Avg Volume
- 26.09M
Get TickerSpark's AI analysis on LPTX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our LPTX Coverage
We haven't published any research on LPTX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate LPTX Report →